With that in mind, let's take a closer look at Medtronic's business, and see what CAPS investors are saying about the stock right now.
Medtronic facts
|
Headquarters (founded)
|
Minneapolis (1949)
|
|
Market Cap
|
$32.99 billion
|
|
Industry
|
Health-Care Equipment
|
|
TTM Revenue
|
$14.63 billion
|
|
Management
|
CEO William Hawkins III (since 2007)
CFO Gary Ellis (since 2005)
|
|
Return on Equity (average, last three years)
|
22.7%
|
|
Dividend Yield
|
2.5%
|
|
Competitors
|
Abbott Labs (NYSE: ABT)
Boston Scientific (NYSE: BSX)
|
|
CAPS members bullish on MDT also bullish on
|
Johnson & Johnson (NYSE: JNJ)
Apple (Nasdaq: AAPL)
|
|
CAPS members bearish on MDT also bearish on
|
Microsoft (Nasdaq: MSFT)
Google (Nasdaq: GOOG)
|
Sources: Capital IQ, a division of Standard & Poor's, and Motley Fool CAPS. TTM = trailing 12 months.
Over on CAPS, some 93% of the 1,028 members who have rated Medtronic
believe the stock will outperform the S&P 500 going forward. These
bulls include fellow Fool Matt Koppenheffer (TMFKopp) and All-Star OpesPerPrudentia, who is ranked in the top 3% of our community.
Last month,
Matt tapped the stock as a possible portfolio-healing device: "There
are a lot of reasons to be bullish here. Good position in its markets,
should have a growing market, and the stock should be relatively
defensive during the recession."
In a pitch from January, OpesPerPrudentia expands on the booming trend working in Medtronic's favor:
The healthcare industry in the United States has
nothing but growth ahead of it as increasing numbers of Boomers require
healthcare and medical electronics that hospitals and standard
in-office practices simply will not be able to keep up with. Any
company with this kind of cash flow that aims to put medical tech in
the hands of homecare outfits and even patients will explode with every
passing year.
Copyright © 2009 Universal Press Syndicate.
Post new comment